Improvement in eHealth, Inc.'s EHTH Y/Y applications growth came at a higher marketing cost, and resulted in in-line 3Q results.
“Visibility into the details of heath care reforms and MLR changes remains poor, keeping us on the sidelines,” Jefferies & Company writes. “We're maintaining a Hold rating, while raising our fair value to $14.”
3Q10 results came in-line with consensus for revenue and EPS, while applications grew 9% Y/Y, up from (3%) in 2Q10. Adds Jefferies & Company, “At $13.47, EHTH is trading at EV/EBITDA of 5.5x and a P/E of 23.6x our FY10 estimates. Our $14 PT is derived using a five-year DCF and implies an EV/EBITDA multiple of 5.1x. Risks include carrier concentration and consolidation, regulatory changes, and investments in new initiatives.”
eHealth currently trades at $13.47.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in